Welcome - Home - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Viewing report Order by Fax Printer Friendly PDF Brochure Send to Friend Enquire before Buying Hard Copy Electronic Amyotrophic Lateral Sclerosis: A route to larger CNS markets? Datamonitor, Oct 2003, Pages: 43   Description     Table of Contents        Enquire before Buying    Send to a Friend   Amyotrophic Lateral Sclerosis (ALS) is an orphan neurodegenerative disease which effects approximately 11,000 people across the seven major markets. ALS is set to provide a platform for drugs use more widespread conditions such as Parkinson's Disease (PD) or Alzheimer's Disease (AD). This Brief provides an insight into key drugs currently in clinical trials for ALS using key opinion leader primary research to validate conclusions. ALS is one of many orphan diseases in the CNS arena. If significant return of investment is to be realized in this market, both existing and future players must address the lack of disease awareness amongst physicians. This research believes that educating physicians is key to improving diagnosis and treatment rates, in addition to establishing good relationships with ALS research organizations. Currently the only prescription drug approved for ALS is Aventis' Rilutek (riluzole). Despite the fact that many physicians doubt its true therapeutic value, Rilutek sales still topped $100m in 2002. This demonstrates the scope for commercial opportunities within the ALS market. Scope and coverage - Epidemiology and prevalence data - Current treatment and unmet market needs - Analysis of trial data, the therapeutic potential of current and future drugs and drug classes - Analysis of key issues in the ALS and orphan disease market supported by key opinion leader interviews Key findings and highlights - ALS is one of many orphan diseases in the CNS arena. If significant return of investment is to be realized in this market, both existing and future players must address the lack of disease awareness amongst physicians. - Currently the only prescription drug approved for ALS is Aventis Rilutek (riluzole). Despite the fact that, many physicians doubt its true therapeutic value, Rilutek sales topped $100m in 2002. This demonstrates the scope for commercial opportunities which can be further increased by seeking approval for lucrative indications such as AD or PD. Why should you buy this brief? - Assess the ALS patient potential - Identify the key unmet needs and diagnostic tools, which would highlight novel targets - Review the therapeutic and commercial potential of drugs and compounds in clinical trials based on ALS expert opinion and trial data Customers who bought this item also bought Amyotrophic Lateral Sclerosis: A route to larger CNS markets? Orphan Diseases in the CNS Market The CNS Market Outlook to 2010 The Outlook For Niche CNS Disorders: Commercial Opportunities In Developing Markets The CNS Outlook to 2007 PharmaWatch: CNS Neuroprotection - Drugs, Markets and Companies CNS Market Analysis 2002: Commercial Viability of Four Dynamic CNS Markets

		Top of page

All rights reserved. � Copyright 2008 Research and Markets    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster